Medtronic spinoff raises millions
Medtronic spinoff MiniMed raised $560 million in its Nasdaq IPO, seeking to expand its diabetes tech portfolio while Medtronic retains majority control.
The IPO priced at $14 per share, valuing the new company at around $3.6 billion. MiniMed plans to use the funds to develop new insulin pumps and continuous glucose monitoring systems. Medtronic's decision to spin off MiniMed reflects a broader trend of large healthcare companies streamlining their operations. By focusing on its core businesses, Medtronic aims to improve its overall growth and profitability. The IPO could signal increased investor interest in diabetes technology, a market driven by the rising prevalence of diabetes globally. MiniMed's success as an independent entity will depend on its ability to innovate and compete with established players like Dexcom and Abbott.
